All In Biotech

Drug Trial Radar · NCT05516979

A Safety & Efficacy Study of Treatment With AP1189 in Rheumatoid Arthritis Patients naïve to DMARD Treatment

A Double-blind, Multi-center, Randomized, Placebo-controlled Study of the Safety and Efficacy of 12 Weeks Extended Treatment With AP1189 in Early Rheumatoid Arthritis (RA) Patients naïve to DMARD Treatment

Last checked: Nov 19, 2026Latest source record: Nov 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 127 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

127

Actual

Start

Sep 26, 2022

Primary completion

Jul 20, 2023

Study completion Jul 20, 2023

Sponsor

Lead sponsor
SynAct Pharma ApsIndustry
Sponsor type
Industry
Collaborators
NBCD A/S
First posted
Aug 26, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of 12 weeks daily treatment with 100 mg AP1189 in RA patients who are to start up-titration with methotrexate (MTX).

Conditions

  • Rheumatoid Arthritis

Interventions

  • 100 mg AP1189Drug

    AP1189 tablets for oral use

  • PlaceboDrug

    Matching placebo for oral use

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of reported AEsTime frame: 12 weeks
  2. Change in ACR20Time frame: 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Timofei Mosneaga Republican Clinical Hospital

    Chisinau, Moldova

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.